{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:35:26Z","timestamp":1757781326287,"version":"3.41.2"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Carbohydrate antigen (CA 19-9) is the most validated marker for both sensitivity and specificity of pancreatic adenocarcinoma used to aid diagnosis of symptomatic patients as well as to evaluate the progression or treatment of disease. Though higher levels of CA 19-9 tend to correlate with neoplastic disease, elevated levels are also often seen in patients with benign gastrointestinal diseases, such as obstructive jaundice and pancreatitis. We present a case of a 74-year-old male who was admitted for abdominal pain and worsening jaundice who was diagnosed with extensive pancreatic necrosis and an underlying invasive pancreatic adenocarcinoma whose serum level of CA 19-9 was found to be extraordinarily high.<\/jats:p>","DOI":"10.1093\/jscr\/rjad550","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:47:25Z","timestamp":1697392045000},"source":"Crossref","is-referenced-by-count":1,"title":["Extraordinarily high serum CA 19-9 in setting of pancreatic necrosis and underlying pancreatic adenocarcinoma: a case report"],"prefix":"10.1093","volume":"2023","author":[{"given":"Ashlyn","family":"McConnell","sequence":"first","affiliation":[{"name":"Department of Surgery, Princeton Baptist Medical Center , Birmingham, AL 35211, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Stoneman","sequence":"additional","affiliation":[{"name":"Edward Via College of Osteopathic Medicine , Spartanburg, SC 29303, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Hewlett","sequence":"additional","affiliation":[{"name":"Department of Surgery, Princeton Baptist Medical Center , Birmingham, AL 35211, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"key":"2023101517471730000_ref1","first-page":"350","article-title":"The clinical utility of the CA 19-9 tumor-associated antigen","volume":"85","author":"Steinberg","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"2023101517471730000_ref2","first-page":"247","volume-title":"CA 19\u20139: Biochemical and Clinical Aspects. Advances in Experimental Medicine and Biology","author":"Scar\u00e0","year":"2015"},{"key":"2023101517471730000_ref3","doi-asserted-by":"crossref","first-page":"8820","DOI":"10.1038\/s41598-020-65720-8","article-title":"Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"2023101517471730000_ref4","article-title":"A case of Choledocholithiasis and obstructive jaundice with a very high serum carbohydrate antigen 19-9 (CA 19-9) level: a case report and review of literature","volume":"14","author":"Ghallab","year":"2022","journal-title":"Cureus"},{"key":"2023101517471730000_ref5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4240\/wjgs.v12.i12.468","article-title":"Carbohydrate antigen 19-9 - tumor marker: past, present, and future","volume":"12","author":"Lee","year":"2020","journal-title":"World J Gastroint Surg"},{"key":"2023101517471730000_ref6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MAJ.0b013e3181f0e2a0","article-title":"CA 19-9 level in patients with type 2 diabetes mellitus and its relation to the metabolic control and microvascular complications","volume":"341","author":"Gul","year":"2011","journal-title":"Am J Med Sci"},{"key":"2023101517471730000_ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/745189","article-title":"Serum CA19-9 level associated with metabolic control and pancreatic beta cell function in diabetic patients","volume":"2012","author":"Yu","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"2023101517471730000_ref8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1055-3207(18)30286-2","article-title":"CA 19\u20139 in pancreatic cancer","volume":"7","author":"Ritts","year":"1998","journal-title":"Surg Oncol Clin N Am"}],"container-title":["Journal of Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jscr\/article-pdf\/2023\/10\/rjad550\/52137702\/rjad550.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jscr\/article-pdf\/2023\/10\/rjad550\/52137702\/rjad550.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:47:30Z","timestamp":1697392050000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jscr\/article\/doi\/10.1093\/jscr\/rjad550\/7317494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jscr\/rjad550","relation":{},"ISSN":["2042-8812"],"issn-type":[{"type":"electronic","value":"2042-8812"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,10]]},"article-number":"rjad550"}}